Repositioning Candidate Details
| Candidate ID: | R0590 |
| Source ID: | DB03619 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Deoxycholic acid |
| Synonyms: | (3α,5β,12α)-3,12-dihydroxycholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 7α-deoxycholic acid; Deoxycholate; Deoxycholic acid; Desoxycholic acid |
| Molecular Formula: | C24H40O4 |
| SMILES: | [H][C@@]12CC[C@H]([C@H](C)CCC(O)=O)[C@@]1(C)[C@@H](O)C[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C |
| Structure: |
|
| DrugBank Description: | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical procedures. |
| CAS Number: | 83-44-3 |
| Molecular Weight: | 392.572 |
| DrugBank Indication: | For improvement in appearance of moderate to severe fullness associated with submental fat in adults. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | As a bile acid, deoxycholic acid emulsifies fat in the gut. Synthetically derived deoxycholic acid, when injected, stimulates a targeted breakdown of adipose cells by disrupting the cell membrane and causing adipocytolysis. This results in an inflammatory reaction and clearing of the adipose tissue remnants by macrophages. Deoxycholic acid's actions are reduced by albumin and tissue-associated proteins, therefore its effect is limited to protein-poor subcutaneous fat tissue. Protein-rich tissues like muscle and skin are unaffected by deoxycholic acid, contributing to its safety profile. |
| Targets: | Steroid Delta-isomerase; PpcA; Elongation factor Tu GTP-binding domain-containing protein 1; Choloylglycine hydrolase; Lactaldehyde dehydrogenase; Acriflavine resistance protein B; Cytochrome c oxidase subunit 1; Cytochrome c oxidase subunit 2; Bile acid receptor; Glutathione S-transferase P; G-protein coupled bile acid receptor 1 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|